Yet another bispecific, humanized IgG1 antibody that is under investigation is zenocutuzumab (MCLA-128), which functions by using two unbiased mechanisms of action: inhibition of HER2–HER3 signalling and elimination of tumour cells by way of ADCC. MCLA-128 capabilities by way of a ‘dock and block’ mechanism whereby one arm with the https://www.directivepublications.org/journal-of-clinical-breast-cancer/